Tag Archives: Drugs

Are pharmaceutical mega-mergers in the public interest?

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Legal High Lies

It was terribly sad listening to the bother of a “legal high” victim on the radio this morning. The now banned N-Bomb LSD copycat drug had left his brother severely brain damaged and dependent on 24 hour care for the … Continue reading

Posted in Drugs | Tagged , , , , | Leave a comment

Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.

The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading

Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban | Tagged , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Bad for patients and bad for growth?

2020health today publish a review from a patient’s perspective of the Government’s plans to change the way medicines are priced. Featured in today’s FT (£) we point out that patients are usually blissfully unaware of pricing negotiations but the Government’s … Continue reading

Posted in Innovation, Patients | Tagged , , , , , , , , , , | Leave a comment

Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing

Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading

Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing | Tagged , , , , , , , , , , , , | 1 Comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Do private patients in the UK help or harm the NHS?

Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading

Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment